Astellas, Seeking Sales in India, Opens Mumbai Office (India)
This article was originally published in PharmAsia News
Astellas Pharma Inc. recently opened the doors of an office in Mumbai, India. The new facility offers Astellas a major opportunity to access the fast growing Indian pharmaceutical market. Currently, the country's drug market is valued at $6.2 billion, making it the number four market in Asia. According to projections by McKinsey & Co. that figure will soar 12 percent every year to $20 billion in 2015. The Asian market outside of Japan presently makes up only 3 percent of Astellas' revenue, a fact the company plans to change in the face of tightening drug pricing restrictions in Japan. (Click here for more - May Require Free Registration
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.